Results 121 to 130 of about 10,662 (153)

A Complete Picture of the CYP2D6 Heterogeneity in Northeastern Italian Genetic Isolates. [PDF]

Int J Mol Sci
Tesolin P, Nardone GG, Santin A, Pecori A, Ruberto R, Concas MP, Zampieri S, Girotto G.   +7 more
europepmc   +1 more source

How CYP2D6 Polymorphism Modulates the Community-Wide Risk of Plasmodium vivax Infection: A Panel Study in Amazonian Brazil. [PDF]

J Infect Dis
Puça MCSB, Naziazeno IM, Santos VCFD, Rodrigues PT, Calil PR, Ladeia WA, Gil JP, Ferreira MU, Nobrega De Sousa T.   +8 more
europepmc   +1 more source

Solanidine-derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients. [PDF]

Br J Clin Pharmacol
Sarömba JA, Müller JP, Tupiec J, Roeth A, Kurt B, Kahles F, Laurentius T, Bollheimer C, Stingl JC, Just KS.   +9 more
europepmc   +1 more source

Der Einfluss des Body-Mass-Index auf die Pharmakokinetik von Methadon [PDF]

, 2009
Wicht, Albert
core  

Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine in lactation. [PDF]

J Pharmacokinet Pharmacodyn
Pan X, Rowland Yeo K.
europepmc   +1 more source

Clinical and pharmacogenomic predictors of survival in tamoxifen treated breast cancer female patients: a real-world study. [PDF]

BMC Cancer
Al-Matrafi AR, Bedair KF, Srinivasan S, Palmer C, Campbell A, Hayward C, Pearson ER, Petty RD.   +7 more
europepmc   +1 more source

Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity. [PDF]

Clin Pharmacol Ther
Kehinde O, Vaughn SE, Amaeze O, Toren P, Retke B, Oni-Orisan A, Ramsey LB.   +6 more
europepmc   +1 more source

Development and Characterization of pFluor50, a Fluorogenic-Based Kinetic Assay System for High-Throughput Inhibition Screening and Characterization of Time-Dependent Inhibition and Inhibition Type for Six Human CYPs. [PDF]

Molecules
Shriwas P, Revnew A, Roo S, Bender A, Miller K, Hadad CM, Lane TR, Ekins S, McElroy CA.   +8 more
europepmc   +1 more source

CYP2D6 Pharmacogenetics in Nigerian Sickle Cell Disease: Phase 1 of Implementing Pharmacogenomics Testing for Effective Care and Treatment in Africa (iPROTECTA) program. [PDF]

Gates Open Res
Adeagbo B, Olarewaju O, Orherhe O, Chikwambi Z, Mazhindu A, Bolarinwa R, Bolaji O, Masimirembwa C, Consortium for Genomics and Therapeutics in Africa.   +8 more
europepmc   +1 more source

Pharmaco- and therapygenetic aspects in the treatment of anxiety disorders beyond the serotonergic system: a brief review [PDF]

, 2012
Bagdy, György, Döme, Péter, Faludi, Gábor, Gonda, Xénia   +3 more
core